Edwards’ Peripheral Artery Growth-Factor Data Pooled By NIH’s Lederman
This article was originally published in The Pink Sheet Daily
Intermittent claudication endpoint in Edwards/Sangamo gene-therapy compound study promoted by National Heart, Lung & Blood Institute principal investigator Lederman at Transcatheter Cardiovascular Therapeutics conference.
You may also be interested in...
The federal government is on the verge of ensuring that 90% of Medicare-eligible people receive prescription drug coverage, HHS Secretary Leavitt said.
HHS Office of Inspector General will decide whether GlaxoSmithKline can donate medicines to Part D-enrolled patients.
BioScrip will be the only provider of Medicare Part B-covered drugs through the competitive acquisition program for three years.